NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity.

ABSTRACT:

Background

Cancer immunotherapy approaches that elicit immune cell responses, including T and NK cells, have revolutionized the field of oncology. However, immunosuppressive mechanisms restrain immune cell activation within solid tumors so additional strategies to augment activity are required.

Methods

We identified the co-stimulatory receptor NKG2D as a target based on its expression on a large proportion of CD8+ tumor infiltrating lymphocytes (TILs) from breast cancer patient samples. Human and murine surrogate NKG2D co-stimulatory receptor-bispecifics (CRB) that bind NKG2D on NK and CD8+ T cells as well as HER2 on breast cancer cells (HER2-CRB) were developed as a proof of concept for targeting this signaling axis in vitro and in vivo.

Results

HER2-CRB enhanced NK

SUBMITTER: Herault A 

PROVIDER: S-EPMC11306676 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature